RaQualia Pharma Inc
TSE:4579
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
301
1 429
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
RaQualia Pharma Inc
EPS (Diluted)
RaQualia Pharma Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
RaQualia Pharma Inc
TSE:4579
|
EPS (Diluted)
-ÂĄ29
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-31%
|
CAGR 10-Years
14%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
EPS (Diluted)
ÂĄ20
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
EPS (Diluted)
ÂĄ151
|
CAGR 3-Years
67%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-11%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
EPS (Diluted)
ÂĄ850
|
CAGR 3-Years
61%
|
CAGR 5-Years
26%
|
CAGR 10-Years
12%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
EPS (Diluted)
ÂĄ241
|
CAGR 3-Years
-12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
21%
|
|
|
Astellas Pharma Inc
TSE:4503
|
EPS (Diluted)
ÂĄ69
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-1%
|
|
RaQualia Pharma Inc
Glance View
RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. The company is headquartered in Nagoya, Aichi-Ken and currently employs 67 full-time employees. The company went IPO on 2011-07-20. The firm is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The firm is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.
See Also
What is RaQualia Pharma Inc's EPS (Diluted)?
EPS (Diluted)
-29.6
JPY
Based on the financial report for Sep 30, 2025, RaQualia Pharma Inc's EPS (Diluted) amounts to -29.6 JPY.
What is RaQualia Pharma Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
14%
Over the last year, the EPS (Diluted) growth was -17%.